Literature DB >> 33181123

Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them.

George E Koch1, Woodson W Smelser1, Sam S Chang2.   

Abstract

Intravesical therapy for nonmuscle invasive bladder cancer decreases recurrence and progression but carries a high risk of side effects, which limit patient adherence. Appropriate management of the toxicities from intravesical therapy requires consideration of the agent used, the side effects experienced, and the timing of those side effects. Management strategies for intravesical toxicities ideally improve patient tolerance without sacrificing oncologic outcomes. This review aims to provide a comprehensive overview of the available evidence regarding the side effects of intravesical therapies for nonmuscle invasive bladder cancer and to propose practical strategies for toxicity management.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33181123     DOI： 10.1016/j.urology.2020.10.039

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  7 in total

1.  Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial.

Authors:  Yasuyoshi Miyata; Toshifumi Tsurusaki; Yasushi Hayashida; Yushi Imasato; Kosuke Takehara; Daiyu Aoki; Masaharu Nishikido; Junichi Watanabe; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Keisuke Taniguchi; Hideki Sakai
Journal:  BJU Int       Date:  2021-08-24       Impact factor: 5.969

Review 2.  Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials.

Authors:  Se Young Choi; Moon Soo Ha; Jung Hoon Kim; Byung Hoon Chi; Jin Wook Kim; In Ho Chang; Tae-Hyoung Kim; Soon Chul Myung
Journal:  Investig Clin Urol       Date:  2022-03

3.  A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches.

Authors:  Ehsan Jahangirian; Ghadir A Jamal; MohammadReza Nouroozi; Alemeh Mohammadpour
Journal:  Int J Pept Res Ther       Date:  2022-02-24       Impact factor: 2.191

4.  Bacillus Calmette-Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract.

Authors:  Tsubasa Kondo; Toshifumi Tsurusaki; Akihiro Asai; Kuniko Abe
Journal:  Urol Case Rep       Date:  2022-07-07

5.  Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.

Authors:  Ilaria Lucca; Laurent Derré; Valérie Cesson; Perrine Bohner; François Crettenand; Sonia Rodrigues-Dias; Florence Dartiguenave; Audrey Masnada; Carla Texeira-Pereira; Sulayman Benmerzoug; Mathieu Chevalier; Sonia Domingos-Pereira; Sylvain Nguyen; Lenka Polak; Anna Schneider; Beat Roth; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Eur Urol Open Sci       Date:  2022-10-03

6.  Novel dihydroartemisinin derivative Mito-DHA5 induces apoptosis associated with mitochondrial pathway in bladder cancer cells.

Authors:  Linfan Xiao; Cangcang Xu; Peiyu Lin; Lingli Mu; Xiaoping Yang
Journal:  BMC Pharmacol Toxicol       Date:  2022-01-20       Impact factor: 2.483

7.  Reactive Arthritis After Intravesical Bacillus Calmette-Guérin Therapy.

Authors:  Yoshinori Taniguchi; Hirofumi Nishikawa; Takahito Kimata; Yasuhiko Yoshinaga; Shigeto Kobayashi; Yoshio Terada
Journal:  J Clin Rheumatol       Date:  2022-03-01       Impact factor: 3.902
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.